Foundation for innovation
in Cardiometabolism and Nutrition

Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab

Digestive and Liver Disease

Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab

Publié le 

Restez en contact

Recevez toute l’actualité de la fondation ICAN

This field is for validation purposes and should be left unchanged.

Nos fondateurs

CERTIFIÉ ISO 9001

Nos soutiens institutionnels

Notre réseau